Think carefully about your first drug choice for UC

Before worrying about positioning new and subsequent therapies in moderate to severe ulcerative colitis, plan for the patient’s first biologic drug to be “forever” – that’s the advice from Professor John Marshall . Speaking at AGW 2019, the director of gastroenterology at Canada’s McMaster University said bio-naive patients were the most responsive. “Protect and optimise ...

Already a member?

Enter your email to keep reading.